Skye Bioscience, Inc.
Clinical-stage biotech developing a CB1-inhibiting antibody for obesity and metabolic diseases.
SKYE | US
Overview
Corporate Details
- ISIN(s):
- US83086J2006
- LEI:
- Country:
- United States of America
- Address:
- 11250 EL CAMINO REAL, SUITE 100, 92130 SAN DIEGO
- Website:
- https://skyebioscience.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Skye Bioscience, Inc. is a clinical-stage biotechnology company developing next-generation drugs for obesity and other metabolic diseases. The company focuses on advancing first-in-class molecules that modulate G-protein coupled receptors (GPCRs). Its lead candidate, nimacimab, is a peripheral CB1-inhibiting antibody being developed as a potential anti-obesity therapeutic. By targeting CB1 receptors in peripheral tissues, nimacimab aims to increase energy expenditure, promote fat breakdown, and offer a differentiated treatment with better gastrointestinal tolerability and muscle preservation. The company initiated its Phase 2 clinical study for nimacimab in August 2024, with data readouts anticipated in 2025.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Skye Bioscience, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Skye Bioscience, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Skye Bioscience, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
